A PCR-based method of screening-individuals of all ages, from neonates to the elderly, for familial hyperaldosteronism type I

Australian and New Zealand Journal of Medicine

Volumn 27, Issue 6, 1997, Pages 685-690

  Stowasser, M ^a   Gartside, M G ^a   Gordon, R D ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Aldosterone; Familial; Gene; Hybrid; Hyperaldosteronism; Primary aldosteronism

Indexed keywords

ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENE ISOLATION; HUMAN; HYPERALDOSTERONISM; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; SCREENING TEST;

EID: 0031425008     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1997.tb00999.x     Document Type: Article

References (24)

1. New MI, Oberfield SE, Levine LS et al. Autosomal dominant transmission and absence of HLA linkage in dexamethasone suppressible hyperaldosteronism (letter). Lancet 1980; ii: 550-1.
2. Ganguly A, Grim CE, Bergstein J, Brown RD, Weinberger MH. Genetic and pathophysiologic studies of a new kindred with glucocorticoid-suppressible hyperaldosteronism manifest in three generations. J Clin Endocrinol Metab 1981; 53: 1040-6.
3. Rich GM, Ulick S, Cook S, Wang JZ, Lifton RP, Dluhy RG. Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med 1992; 116: 813-20.
4. Sutherland DJA, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966; 95: 1109-19.
5. Salti IS, Stiefel M, Ruse JL, Laidlaw JC. Non-tumorous 'primary' aldosteronism: I. Type relieved by glucocorticoid (glucocorticoid-remediable aldosteronism). Can Med Assoc J 1969; 101: 1-10.
6. Gill JR, Bartter FC. Overproduction of sodium-retaining steroids by the zona glomerulosa is adrenocorticotropin-dependent and mediates hypertension in dexamethasone-suppressible aldosteronism. J Clin Endocrinol Metab 1981; 53: 331-7.
7. Woodland E, Tunny TJ, Hamlet SM, Gordon RD. Hypertension corrected and aldosterone responsiveness to renin-angiotensin restored by long-term dexamethasone in glucocorticoid-suppressible hyperaldosteronism. Clin Exp Pharmacol Physiol 1985; 12: 245-8.
8. Stowasser M, Gordon RD, Klemm SA, Tunny TJ. Reninaldosterone response to dexamethasone in glucocorticoid-suppressible hyperaldosteronism is altered by coexistent renal artery stenosis. J Clin Endocrinol Metab 1993; 77: 800-4.
9. Lifton RP, Dluhy RG, Powers M et al. A chimaeric 11ß-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355: 262-5.
10. Lifton RP, Dluhy RG, Powers M et al. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet 1992; 2: 66-74.
11. Fallo F, Sonino N, Armanini D et al. A new family with dexamethasone-suppressible hyperaldosteronism: aldosterone unresponsiveness to angiotensin II. Clin Endocrinol 1985; 22: 777-85.
12. Connell JMC, Kenyon CJ, Corrie JET, Fraser R, Watt R, Lever AF. Dexamethasone-suppressible hyperaldosteronism: adrenal transitional cell hyperplasia? Hypertension 1986; 8: 669-76.
13. Stowasser M, Bachmann AW, Jonsson JR, Tunny TJ, Klemm SA, Gordon RD. Hybrid gene or hybrid steroids in the detection and screening for Familial Hyperaldosteronism Type I. CHn Exp Pharmacol Physiol 1995; 22: 444-6.
14. Stowasser M, Bachmann AW, Jonsson JR, Tunny TJ, Klemm SA, Gordon RD. Clinical, biochemical and genetic approaches to the detection of Familial Hyperaldosteronism Type I. J Hypertens 1995; 13: 1610-3.
15. Ganguly AG, Melada GA, Luetscher JA, Dowdy AJ. Control of plasma aldosterone in primary aldosteronism: distinction between adenoma and hyperplasia. J Clin Endocrinol Metab 1973; 37: 765-75.
16. Wisgerhof M, Brown RD, Hogan MJ, Carpenter PC, Edis AJ. The plasma aldosterone response to angiotensin II infusion in aldosterone-producing adenoma and idiopathic hyperaldosteronism. J Clin Endocrinol Metab 1981; 52: 195-8.
17. Gordon RD, Gomez-Sanchez CE, Hamlet SM, Tunny TJ, Klemm SA. Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin essential hypertension. J Hypertens 1987; 5 (Suppl. 5): S103-S106.
18. Ulick S, Chu MD. Hypersecretion of a new corticosteroid, 18-hydroxycortisol in two types of adrenocortical hypertension. Clin Exp Hypertens 1982; A4: 1771-7.
19. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD. A new genetic test for Familial Hyperaldosteronism Type I aids in the detection of curable hypertension. Biochem Biophys Res Comm 1995; 207: 565-71.
20. Jamieson A, Slutsker L, Inglis GC, Fraser R, White PC, Connell JMC. Glucocorticoid-suppressible hyperaldosteronism: effects of crossover site and parental origin of chimaeric gene on phenotypic expression. Clin Sci 1995; 88: 563-70.
21. Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism (GRA): diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids 1995; 60: 48-51.
22. Miyahara K, Kawamoto T, Mitsuuchi Y et al. The chimeric gene linked to glucocorticoid-suppressible hyperaldosteronism encodes a fused P-450 protein possessing aldosterone synthase activity. Biochem Biophys Res Commun 1992; 189: 885-91.
23. Cheng S, Chang S-Y, Gravitt P, Respess R. Long-PCR. Nature 1994; 369: 684-5.
24. Jamieson A, Inglis GC, Campbell M, Fraser R, Connell JMC. Rapid diagnosis of glucocorticoid suppressible hyperaldosteronism in infants and adolescents. Arch Dis Child 1994; 71: 40-3.